What’s the current market cap for CeriBell, Inc. stock?

CeriBell, Inc. (CBLL) has a market cap of $705m as of June 16, 2026.

What is the P/E ratio for CeriBell, Inc. stock?

The price to earnings (P/E) ratio for CeriBell, Inc. (CBLL) stock is 0 as of June 16, 2026.

Does CeriBell, Inc. stock pay dividends?

No, CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next CeriBell, Inc. dividend payment date?

CeriBell, Inc. (CBLL) stock does not pay dividends to its shareholders.

What is the beta indicator for CeriBell, Inc.?

CeriBell, Inc. (CBLL) does not currently have a Beta indicator.

Buy CeriBell, Inc. stock | $CBLL Share Price

13:30

09:10

04:45

00:25

20:00

About CeriBell, Inc.

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Ticker

$CBLL

Sector

Health

Primary listing

NASDAQ

Employees

327

Headquarters

Sunnyvale, United States

Website

www.ceribell.com

CeriBell, Inc. Metrics

BasicAdvanced

$705m

-$1.63

Bulls say / Bears say

Strong revenue growth: total revenue reached $89.1 million in 2025, rising 36% year-over-year as the company expanded into new and existing accounts. (SEC)

Full-year 2025 gross margin stood at 88%, driven by a premium product mix and operational leverage. (SEC)

In Q4 2025, the company achieved important regulatory milestones: FDA 510(k) clearances for delirium continuous monitoring and neonatal seizure detection, as well as a Breakthrough Device Designation for its LVO stroke solution, broadening its addressable markets. (SEC)

Net loss widened to $53.4 million in FY2025 from $40.5 million in 2024, highlighting continued difficulties in reaching profitability. (SEC)

Operating expenses jumped 42% to $136.7 million in 2025, growing faster than revenue and putting additional pressure on margins. (SEC)

Guidance for 2026 revenue is $111 million to $115 million, a projected growth rate of 25–29%, which is slower than the 36% growth seen in 2025, suggesting potential slowdown ahead. (SEC)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CBLL

Capital at risk

Market closed

Upcoming events

No upcoming events